4D Molecular Therapeutics, Inc. (FDMT) Guidance & Earnings Results

On 2025-11-10 4D Molecular Therapeutics, Inc. reaffirmed guidance: "Cash runway into H2…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

FDMT4D Molecular Therapeutics, Inc.Follow FDMT — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 779.5M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 11 Nov, in 17 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
10 Nov 25	Reaffirmed	Cash runway into H2 2028 · full year

4D Molecular Therapeutics, Inc. — questions

What guidance did 4D Molecular Therapeutics, Inc. give?: On 2025-11-10: "Cash runway into H2 2028"
When does 4D Molecular Therapeutics, Inc. report earnings?: 4D Molecular Therapeutics, Inc.'s next earnings report is expected on 2026-11-11.

Every figure on this page comes from 4D Molecular Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.